glp-1 kidney Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic disease through dampening the receptor for advanced glycation end products–induced inflammation SGLT2 Inhibitors and GLP-1 Receptor
Description
Sassa S
It was originally approved by the FDA for type 2 diabetes and is now also approved for weight management in eligible patients
Stratified by placebo control or active control Considering the RCTs including placebo and active control, we performed a subgroup analysis between them
The study did find higher rates of gastrointestinal issues among those using the medicines, side effects that many people encounter on the drugs
Julie Mary Mani, M.D
